Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 4 April 2026
2024-04-30 09:30:00 Tuesday ET

With clean and green energy resources and electric vehicles, the global auto industry now navigates at a newer and faster pace. Both BYD and Tesla have
2017-09-19 05:34:00 Tuesday ET

Facebook, Twitter, and Google executives head before the Senate Judiciary Committee to explain the scope of Russian interference in the U.S. presidential el
2026-07-01 11:29:00 Wednesday ET

In recent years, higher American economic growth has been impressive both by historical standards and in comparison to the rest of the world. American excep
2017-01-23 09:30:00 Monday ET

There are several highlights from the first news conference after Trump's presidential election victory: The Trump administration will repeal-and-
2023-02-03 08:27:00 Friday ET

Our proprietary alpha investment model outperforms most stock market indices from 2017 to 2023. Our proprietary alpha investment model outperforms the ma
2022-10-25 11:31:00 Tuesday ET

Corporate investment insights from mergers and acquisitions Relative market misvaluation between the bidder and target firms drives most waves of mergers